DK2190863T3 - New albumin binding compositions, methods and uses - Google Patents
New albumin binding compositions, methods and uses Download PDFInfo
- Publication number
- DK2190863T3 DK2190863T3 DK08786222.3T DK08786222T DK2190863T3 DK 2190863 T3 DK2190863 T3 DK 2190863T3 DK 08786222 T DK08786222 T DK 08786222T DK 2190863 T3 DK2190863 T3 DK 2190863T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- albumin
- polypeptide
- binding
- protein
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title claims 148
- 108010088751 Albumins Proteins 0.000 title claims 148
- 230000027455 binding Effects 0.000 title claims 143
- 238000000034 method Methods 0.000 title claims 16
- 239000000203 mixture Substances 0.000 title claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 155
- 102000004196 processed proteins & peptides Human genes 0.000 claims 149
- 229920001184 polypeptide Polymers 0.000 claims 145
- 108090000623 proteins and genes Proteins 0.000 claims 53
- 102000004169 proteins and genes Human genes 0.000 claims 48
- 235000018102 proteins Nutrition 0.000 claims 44
- 108091006905 Human Serum Albumin Proteins 0.000 claims 35
- 102000008100 Human Serum Albumin Human genes 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 33
- 239000012634 fragment Substances 0.000 claims 33
- 150000001413 amino acids Chemical class 0.000 claims 31
- 241000288906 Primates Species 0.000 claims 26
- 238000002965 ELISA Methods 0.000 claims 22
- 102000007562 Serum Albumin Human genes 0.000 claims 22
- 108010071390 Serum Albumin Proteins 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 235000001014 amino acid Nutrition 0.000 claims 22
- 239000000872 buffer Substances 0.000 claims 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 21
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 229940024606 amino acid Drugs 0.000 claims 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 18
- 108091034117 Oligonucleotide Proteins 0.000 claims 17
- 230000004927 fusion Effects 0.000 claims 17
- 210000002966 serum Anatomy 0.000 claims 17
- 239000001974 tryptic soy broth Substances 0.000 claims 16
- 239000013598 vector Substances 0.000 claims 16
- 230000006870 function Effects 0.000 claims 15
- 230000003993 interaction Effects 0.000 claims 15
- 125000000539 amino acid group Chemical group 0.000 claims 14
- 238000012163 sequencing technique Methods 0.000 claims 14
- 238000011534 incubation Methods 0.000 claims 13
- 238000004458 analytical method Methods 0.000 claims 12
- 238000006243 chemical reaction Methods 0.000 claims 12
- 238000001727 in vivo Methods 0.000 claims 12
- 108020001580 protein domains Proteins 0.000 claims 12
- 238000000746 purification Methods 0.000 claims 12
- 239000000243 solution Substances 0.000 claims 12
- 230000004071 biological effect Effects 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 11
- 238000010790 dilution Methods 0.000 claims 10
- 239000012895 dilution Substances 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 9
- 229960000723 ampicillin Drugs 0.000 claims 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 239000002609 medium Substances 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 8
- 229920001213 Polysorbate 20 Polymers 0.000 claims 8
- 101710120037 Toxin CcdB Proteins 0.000 claims 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 238000002823 phage display Methods 0.000 claims 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 8
- 238000012360 testing method Methods 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 7
- 241000194017 Streptococcus Species 0.000 claims 7
- 238000013019 agitation Methods 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 7
- 230000000903 blocking effect Effects 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 7
- 238000010367 cloning Methods 0.000 claims 7
- 238000009826 distribution Methods 0.000 claims 7
- 238000002474 experimental method Methods 0.000 claims 7
- 239000013612 plasmid Substances 0.000 claims 7
- 239000013615 primer Substances 0.000 claims 7
- 241000588724 Escherichia coli Species 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 230000008878 coupling Effects 0.000 claims 6
- 238000010168 coupling process Methods 0.000 claims 6
- 238000005859 coupling reaction Methods 0.000 claims 6
- 238000000502 dialysis Methods 0.000 claims 6
- 238000005516 engineering process Methods 0.000 claims 6
- 230000001747 exhibiting effect Effects 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 229930027917 kanamycin Natural products 0.000 claims 6
- 229960000318 kanamycin Drugs 0.000 claims 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 6
- 229930182823 kanamycin A Natural products 0.000 claims 6
- 239000013641 positive control Substances 0.000 claims 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 5
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 claims 5
- 239000011543 agarose gel Substances 0.000 claims 5
- 230000005875 antibody response Effects 0.000 claims 5
- 239000011324 bead Substances 0.000 claims 5
- 238000010241 blood sampling Methods 0.000 claims 5
- 229940098773 bovine serum albumin Drugs 0.000 claims 5
- 238000005119 centrifugation Methods 0.000 claims 5
- 238000013461 design Methods 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 5
- 239000000499 gel Substances 0.000 claims 5
- 230000002209 hydrophobic effect Effects 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 239000000047 product Substances 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 238000000954 titration curve Methods 0.000 claims 5
- 108010050327 trypticase-soy broth Proteins 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims 4
- 102000014914 Carrier Proteins Human genes 0.000 claims 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 4
- 238000012181 QIAquick gel extraction kit Methods 0.000 claims 4
- 108020004511 Recombinant DNA Proteins 0.000 claims 4
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims 4
- 108010090804 Streptavidin Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 150000001540 azides Chemical class 0.000 claims 4
- 108091008324 binding proteins Proteins 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 229940041514 candida albicans extract Drugs 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 238000010276 construction Methods 0.000 claims 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000011013 endotoxin removal Methods 0.000 claims 4
- 229940088598 enzyme Drugs 0.000 claims 4
- 230000002068 genetic effect Effects 0.000 claims 4
- 230000000670 limiting effect Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 239000008188 pellet Substances 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 238000003259 recombinant expression Methods 0.000 claims 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- 230000032258 transport Effects 0.000 claims 4
- 239000011534 wash buffer Substances 0.000 claims 4
- 239000012138 yeast extract Substances 0.000 claims 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000008273 gelatin Substances 0.000 claims 3
- 229920000159 gelatin Polymers 0.000 claims 3
- 235000019322 gelatine Nutrition 0.000 claims 3
- 235000011852 gelatine desserts Nutrition 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims 3
- 239000011654 magnesium acetate Substances 0.000 claims 3
- 229940069446 magnesium acetate Drugs 0.000 claims 3
- 235000011285 magnesium acetate Nutrition 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108010025221 plasma protein Z Proteins 0.000 claims 3
- 229910052700 potassium Inorganic materials 0.000 claims 3
- 235000011056 potassium acetate Nutrition 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- 235000011149 sulphuric acid Nutrition 0.000 claims 3
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 108010076119 Caseins Proteins 0.000 claims 2
- 239000003155 DNA primer Substances 0.000 claims 2
- 238000001712 DNA sequencing Methods 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010015866 Extravasation Diseases 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 claims 2
- 239000007836 KH2PO4 Substances 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 229920002684 Sepharose Polymers 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 claims 2
- 238000002835 absorbance Methods 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 239000007478 blood agar base Substances 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 244000309466 calf Species 0.000 claims 2
- 239000005018 casein Substances 0.000 claims 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 2
- 235000021240 caseins Nutrition 0.000 claims 2
- 238000012512 characterization method Methods 0.000 claims 2
- 238000001311 chemical methods and process Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000004087 circulation Effects 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003596 drug target Substances 0.000 claims 2
- 230000009881 electrostatic interaction Effects 0.000 claims 2
- 238000010828 elution Methods 0.000 claims 2
- 230000009088 enzymatic function Effects 0.000 claims 2
- 230000036251 extravasation Effects 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 229940039412 ketalar Drugs 0.000 claims 2
- 229960003299 ketamine Drugs 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 claims 2
- 238000011160 research Methods 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 238000005070 sampling Methods 0.000 claims 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- -1 tendamistats Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000004448 titration Methods 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 102000008102 Ankyrins Human genes 0.000 claims 1
- 108010049777 Ankyrins Proteins 0.000 claims 1
- 108010039627 Aprotinin Proteins 0.000 claims 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 238000000035 BCA protein assay Methods 0.000 claims 1
- 108010077805 Bacterial Proteins Proteins 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 108010006303 Carboxypeptidases Proteins 0.000 claims 1
- 102000005367 Carboxypeptidases Human genes 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 102000012410 DNA Ligases Human genes 0.000 claims 1
- 108010061982 DNA Ligases Proteins 0.000 claims 1
- 101100285402 Danio rerio eng1a gene Proteins 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102000002090 Fibronectin type III Human genes 0.000 claims 1
- 108050009401 Fibronectin type III Proteins 0.000 claims 1
- 241001617393 Finegoldia Species 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 241000417247 Homotherium serum Species 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 108010047357 Luminescent Proteins Proteins 0.000 claims 1
- 102000006830 Luminescent Proteins Human genes 0.000 claims 1
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108010056852 Myostatin Proteins 0.000 claims 1
- 229910021204 NaH2 PO4 Inorganic materials 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000000470 PDZ domains Human genes 0.000 claims 1
- 108050008994 PDZ domains Proteins 0.000 claims 1
- 108010079855 Peptide Aptamers Proteins 0.000 claims 1
- 108010067902 Peptide Library Proteins 0.000 claims 1
- 241000191992 Peptostreptococcus Species 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 1
- 238000012300 Sequence Analysis Methods 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 claims 1
- 108010006785 Taq Polymerase Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000009056 active transport Effects 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000005349 anion exchange Methods 0.000 claims 1
- 238000005571 anion exchange chromatography Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 238000013459 approach Methods 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 238000007845 assembly PCR Methods 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000012148 binding buffer Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000007413 biotinylation Methods 0.000 claims 1
- 230000006287 biotinylation Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical group 0.000 claims 1
- 238000005341 cation exchange Methods 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000012412 chemical coupling Methods 0.000 claims 1
- 238000001142 circular dichroism spectrum Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 102000006834 complement receptors Human genes 0.000 claims 1
- 108010047295 complement receptors Proteins 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 238000004925 denaturation Methods 0.000 claims 1
- 230000036425 denaturation Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000011161 development Methods 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000012520 frozen sample Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 101150023479 hsdS gene Proteins 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000002898 library design Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000012417 linear regression Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000006674 lysosomal degradation Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 210000002500 microbody Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 101150093139 ompT gene Proteins 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 108010054624 red fluorescent protein Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 238000003118 sandwich ELISA Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000010187 selection method Methods 0.000 claims 1
- 230000009834 selective interaction Effects 0.000 claims 1
- 238000013207 serial dilution Methods 0.000 claims 1
- 239000003998 snake venom Substances 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 238000007619 statistical method Methods 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 239000012089 stop solution Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 239000008399 tap water Substances 0.000 claims 1
- 235000020679 tap water Nutrition 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000031998 transcytosis Effects 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 239000007102 tryptic soy broth medium Substances 0.000 claims 1
- 239000012137 tryptone Substances 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96261807P | 2007-07-31 | 2007-07-31 | |
| EP07113533 | 2007-07-31 | ||
| PCT/EP2008/059389 WO2009016043A2 (en) | 2007-07-31 | 2008-07-17 | New albumin binding compositions, methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2190863T3 true DK2190863T3 (en) | 2015-11-30 |
Family
ID=40057660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08786222.3T DK2190863T3 (en) | 2007-07-31 | 2008-07-17 | New albumin binding compositions, methods and uses |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8937153B2 (enExample) |
| EP (2) | EP2546261A3 (enExample) |
| JP (1) | JP5718638B2 (enExample) |
| CN (2) | CN104710518A (enExample) |
| AU (1) | AU2008281913B2 (enExample) |
| CA (1) | CA2694139C (enExample) |
| DE (1) | DE08786222T1 (enExample) |
| DK (1) | DK2190863T3 (enExample) |
| ES (1) | ES2346178T3 (enExample) |
| HK (1) | HK1211040A1 (enExample) |
| WO (1) | WO2009016043A2 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE08786222T1 (de) * | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| EP2437767B1 (en) * | 2009-06-01 | 2015-07-08 | MedImmune, LLC | Molecules with extended half-lives and uses thereof |
| DK2977088T3 (en) * | 2010-03-08 | 2017-10-09 | Ge Healthcare Bioprocess R&D Ab | IMMUNOGLOBULIN G FC REGION BINDING POLYPEPTIDE |
| WO2011136361A1 (ja) * | 2010-04-30 | 2011-11-03 | 株式会社 三和化学研究所 | 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質 |
| TR201809437T4 (tr) * | 2010-07-09 | 2018-07-23 | Affibody Ab | Polipeptitler. |
| AU2011286024B2 (en) * | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2012050923A2 (en) * | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action |
| CN103547590B (zh) | 2010-09-28 | 2017-11-28 | 埃格里昂制药股份有限公司 | 高度可溶性瘦蛋白 |
| CA2818969C (en) | 2010-11-26 | 2020-04-14 | Molecular Partners Ag | Improved n-terminal capping modules for designed ankyrin repeat proteins |
| EA201391753A1 (ru) * | 2011-05-21 | 2014-08-29 | Макродженикс, Инк. | Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке |
| DK2729160T3 (da) * | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
| EP2729481B1 (en) * | 2011-07-08 | 2018-10-17 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
| HRP20190522T1 (hr) | 2012-02-20 | 2019-05-03 | Swedish Orphan Biovitrum Ab (Publ) | Polipeptidi koji se vežu za humani komplement c5 |
| JP2020033372A (ja) * | 2012-03-28 | 2020-03-05 | アフィボディ・アーベー | 経口投与 |
| US20150133373A1 (en) * | 2012-03-28 | 2015-05-14 | Amylin Pharmaceuticals, Llc | Transmucosal delivery of engineered polypeptides |
| KR20140142298A (ko) | 2012-03-28 | 2014-12-11 | 애피바디 에이비 | 경구투여 |
| EP2855509B1 (en) | 2012-05-25 | 2018-05-02 | Janssen Biotech, Inc. | Non-natural consensus albumin binding domains |
| CN104662035A (zh) * | 2012-09-25 | 2015-05-27 | 阿菲博迪公司 | 白蛋白结合多肽 |
| WO2014053586A1 (en) | 2012-10-05 | 2014-04-10 | Affibody Ab | Her3 binding polypeptides |
| AU2013336646B2 (en) | 2012-10-25 | 2016-07-14 | Affibody Ab | ABD binding polypeptide |
| JP6396303B2 (ja) * | 2012-10-25 | 2018-09-26 | アフィボディ・アーベー | アルブミン結合を含有するタンパク質の分離方法 |
| WO2014076179A1 (en) | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
| RU2015142437A (ru) | 2013-03-14 | 2017-04-27 | Дайити Санкио Ко., Лтд | Новые связывающие белки для pcsk9 |
| US10093921B2 (en) | 2013-03-14 | 2018-10-09 | The Governing Council Of The University Of Toronto | Scaffolded peptidic libraries and methods of making and screening the same |
| MX366425B (es) | 2013-03-15 | 2019-07-04 | Affibody Ab | Nuevos polipeptidos. |
| CN106913865A (zh) | 2013-04-18 | 2017-07-04 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| EP3010527B1 (en) | 2013-06-17 | 2018-08-08 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| SI3038633T1 (sl) | 2013-08-28 | 2021-05-31 | Ipc Research, Llc | Stabilni polipeptidi, vezani na humani komplement C5 |
| PL3039033T3 (pl) | 2013-08-28 | 2020-01-31 | Affibody Ab | Polipeptydy wiążące o zmutowanym rusztowaniu |
| HK1226308A1 (zh) | 2013-08-30 | 2017-09-29 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| PL3193930T3 (pl) | 2014-09-17 | 2019-12-31 | Affibody Ab | Nowe polipeptydy |
| KR20170068553A (ko) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | 인터류킨-15 조성물 및 이의 용도 |
| EP3209320B1 (en) | 2014-10-22 | 2023-03-08 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| UA121973C2 (uk) | 2014-10-31 | 2020-08-25 | Нджм Біофармасьютікалз, Інк. | Комплекс, що має активність фактора диференціації росту 15 (gdf15), та способи лікування ним ожиріння та гіперглікемії у суб'єкта |
| MY188784A (en) | 2015-01-12 | 2021-12-31 | Affibody Ab | Il-17a-binding polypeptides |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| EP3291828A4 (en) | 2015-05-06 | 2018-10-03 | Alborz Mahdavi | Glucose responsive insulins |
| KR20180020141A (ko) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | 암 치료에 사용되는 peg화된 인터류킨-10 |
| EA037478B1 (ru) | 2015-08-04 | 2021-04-01 | Дьюк Юниверсити | Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения |
| CN108025040A (zh) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | 使用白介素-10治疗疾病和病症的方法 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| CN107022031A (zh) * | 2016-01-29 | 2017-08-08 | 中国人民解放军军事医学科学院微生物流行病研究所 | 融合蛋白HSA1-Vβ1及其应用 |
| US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
| CN110023326A (zh) | 2016-09-23 | 2019-07-16 | 杜克大学 | 具有lcst行为的非结构化无重复多肽 |
| CN107952080A (zh) * | 2016-10-14 | 2018-04-24 | 中国科学院过程工程研究所 | 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用 |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS |
| EP3665202A1 (en) | 2017-08-09 | 2020-06-17 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
| EP3691693A4 (en) | 2017-10-06 | 2021-08-25 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
| US20200239575A1 (en) * | 2017-10-06 | 2020-07-30 | University Of Utah Research Foundation | A fusion protein for targeted therapy of autoimmune disease |
| WO2019147954A1 (en) * | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| EP3765496A1 (en) | 2018-03-13 | 2021-01-20 | Affibody AB | Polypeptides based on a novel scaffold |
| US12257308B2 (en) | 2018-04-30 | 2025-03-25 | Duke University | Stimuli-responsive PEG-like polymer-based drug delivery platform |
| EP3829622A4 (en) | 2018-08-02 | 2022-05-11 | Duke University | DOUBLE AGONIST FUSION PROTEINS |
| WO2020051541A1 (en) * | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| JP2022521428A (ja) | 2019-02-25 | 2022-04-07 | ザ・ユニバーシティ・オブ・シカゴ | 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物 |
| WO2020245171A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| EP3785726A1 (en) | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| AU2020342349A1 (en) | 2019-09-02 | 2022-03-03 | Biotest Ag | Factor VIII protein with increased half-life |
| WO2021089695A1 (en) | 2019-11-05 | 2021-05-14 | Affibody Ab | Polypeptides |
| US20230190881A1 (en) | 2020-02-17 | 2023-06-22 | Biotest Ag | Subcutaneous administration of factor viii |
| EP3878515A1 (en) * | 2020-03-09 | 2021-09-15 | Hober Biotech AB | Therapeutic agent targeting her2 |
| WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
| WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
| AU2021405360A1 (en) | 2020-12-21 | 2023-06-22 | Affibody Ab | New polypeptide |
| WO2022171892A1 (en) | 2021-02-15 | 2022-08-18 | Affibody Ab | New her2-binding polypeptide |
| CN118632866A (zh) | 2022-02-08 | 2024-09-10 | 阿菲博迪公司 | 结合胸腺基质淋巴细胞生成素的蛋白质z变体及其医疗用途 |
| WO2023225534A1 (en) | 2022-05-18 | 2023-11-23 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
| TW202416938A (zh) | 2022-08-10 | 2024-05-01 | 日商興和股份有限公司 | 親和體微胞(affibody micelle)藥物複合體 |
| AR131869A1 (es) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| CN121038816A (zh) | 2023-05-04 | 2025-11-28 | 阿菲博迪公司 | 新多肽 |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025158010A1 (en) | 2024-01-25 | 2025-07-31 | Affibody Ab | Her2-binding polypeptide |
| CN121041473A (zh) * | 2024-05-29 | 2025-12-02 | 烟台蓝纳成生物技术股份有限公司 | 一种双功能性融合蛋白、放射性核素标记物及其应用 |
| CN118666961B (zh) * | 2024-08-23 | 2024-11-26 | 通化安睿特生物制药股份有限公司 | 人白蛋白特异结合多肽及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| FR2718452B1 (fr) * | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| FR2726471B1 (fr) * | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
| DE19742706B4 (de) * | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9823071D0 (en) * | 1998-10-21 | 1998-12-16 | Affibody Technology Ab | A method |
| GB9911287D0 (en) * | 1999-05-14 | 1999-07-14 | Affibody Technology Sweden Ab | Self-assembling protein structures |
| DE60030323T2 (de) | 1999-12-24 | 2007-10-11 | Genentech, Inc., South San Francisco | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| CN1169827C (zh) | 2001-08-07 | 2004-10-06 | 沈阳三生制药股份有限公司 | 一种增强多肽在体内稳定性药物的生产方法及其应用 |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CA2464690A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| SE0400274D0 (sv) * | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
| EP1732613A2 (en) * | 2004-04-06 | 2006-12-20 | Affibody AB | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
| US7892827B2 (en) * | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| DE08786222T1 (de) * | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| JP5960598B2 (ja) * | 2009-11-04 | 2016-08-02 | アフィボディ・アーベー | Ｈｅｒ３結合ポリペプチド |
-
2008
- 2008-07-17 DE DE08786222T patent/DE08786222T1/de active Pending
- 2008-07-17 ES ES08786222.3T patent/ES2346178T3/es active Active
- 2008-07-17 CN CN201510071238.8A patent/CN104710518A/zh active Pending
- 2008-07-17 JP JP2010518606A patent/JP5718638B2/ja active Active
- 2008-07-17 CA CA2694139A patent/CA2694139C/en active Active
- 2008-07-17 US US12/452,731 patent/US8937153B2/en active Active
- 2008-07-17 AU AU2008281913A patent/AU2008281913B2/en active Active
- 2008-07-17 CN CN200880101168.4A patent/CN101765608B/zh active Active
- 2008-07-17 EP EP12176805.5A patent/EP2546261A3/en not_active Withdrawn
- 2008-07-17 WO PCT/EP2008/059389 patent/WO2009016043A2/en not_active Ceased
- 2008-07-17 DK DK08786222.3T patent/DK2190863T3/da active
- 2008-07-17 EP EP08786222.3A patent/EP2190863B1/en active Active
-
2014
- 2014-11-24 US US14/551,931 patent/US10118949B2/en active Active
-
2015
- 2015-12-02 HK HK15111838.6A patent/HK1211040A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2190863A2 (en) | 2010-06-02 |
| AU2008281913A1 (en) | 2009-02-05 |
| CN101765608A (zh) | 2010-06-30 |
| DE08786222T1 (de) | 2010-11-25 |
| US20150158916A1 (en) | 2015-06-11 |
| EP2190863B1 (en) | 2015-09-02 |
| AU2008281913B2 (en) | 2013-11-07 |
| HK1211040A1 (en) | 2016-05-13 |
| ES2346178T1 (es) | 2010-10-13 |
| EP2546261A2 (en) | 2013-01-16 |
| JP2010534486A (ja) | 2010-11-11 |
| WO2009016043A3 (en) | 2009-06-04 |
| CN104710518A (zh) | 2015-06-17 |
| US10118949B2 (en) | 2018-11-06 |
| US8937153B2 (en) | 2015-01-20 |
| JP5718638B2 (ja) | 2015-05-13 |
| CA2694139A1 (en) | 2009-02-05 |
| US20100273979A1 (en) | 2010-10-28 |
| CN101765608B (zh) | 2015-03-11 |
| WO2009016043A2 (en) | 2009-02-05 |
| CA2694139C (en) | 2018-06-05 |
| ES2346178T3 (es) | 2015-11-02 |
| EP2546261A3 (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2190863B1 (en) | New albumin binding compositions, methods and uses | |
| EP3514169B1 (en) | Designed repeat proteins binding to serum albumin | |
| DK2912054T3 (en) | Albumin-binding polypeptide | |
| JP2018183171A (ja) | アルブミン結合ポリペプチド | |
| WO2024084203A1 (en) | Single domain antibodies binding to albumin | |
| EP4598963A1 (en) | Ultrastable antibody fragments with a novel disuldide bridge | |
| US11505576B2 (en) | Polypeptides based on a scaffold | |
| JP5645155B2 (ja) | 分子量マーカー及び分子量マーカーの作製方法 | |
| HK40059771A (en) | Designed repeat proteins binding to serum albumin | |
| HK40012160B (en) | Designed repeat proteins binding to serum albumin | |
| HK40012160A (en) | Designed repeat proteins binding to serum albumin | |
| HK1189386A (en) | Designed repeat proteins binding to serum albumin |